Analysts Expect Achaogen Inc (AKAO) to Announce -$0.79 Earnings Per Share
Equities analysts expect Achaogen Inc (NASDAQ:AKAO) to report earnings of ($0.79) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Achaogen’s earnings. The highest EPS estimate is ($0.66) and the lowest is ($0.99). Achaogen reported earnings of ($1.04) per share during the same quarter last year, which indicates a positive year over year growth rate of 24%. The firm is scheduled to report its next quarterly earnings results on Tuesday, March 13th.
According to Zacks, analysts expect that Achaogen will report full-year earnings of ($3.06) per share for the current fiscal year, with EPS estimates ranging from ($3.16) to ($2.92). For the next year, analysts expect that the firm will post earnings of ($3.21) per share, with EPS estimates ranging from ($3.73) to ($2.78). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Achaogen.
Achaogen (NASDAQ:AKAO) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.13). The company had revenue of $0.58 million for the quarter, compared to analyst estimates of $2.09 million. Achaogen had a negative net margin of 593.61% and a negative return on equity of 80.44%. The company’s quarterly revenue was down 96.4% on a year-over-year basis. During the same period last year, the business earned ($0.41) EPS.
Shares of Achaogen (NASDAQ AKAO) traded down $0.10 during trading hours on Wednesday, hitting $10.54. 1,251,400 shares of the company’s stock were exchanged, compared to its average volume of 1,410,000. The firm has a market cap of $446.83, a price-to-earnings ratio of -3.14 and a beta of 1.27. Achaogen has a 52 week low of $9.83 and a 52 week high of $27.79. The company has a quick ratio of 6.99, a current ratio of 6.99 and a debt-to-equity ratio of 0.08.
In other Achaogen news, major shareholder Robert W. Duggan bought 50,000 shares of the firm’s stock in a transaction dated Friday, January 5th. The shares were acquired at an average cost of $11.51 per share, for a total transaction of $575,500.00. Following the transaction, the insider now owns 5,617,752 shares in the company, valued at $64,660,325.52. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Robert W. Duggan bought 15,000 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The shares were acquired at an average price of $10.89 per share, for a total transaction of $163,350.00. Following the completion of the transaction, the insider now owns 5,617,752 shares in the company, valued at approximately $61,177,319.28. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 160,012 shares of company stock worth $1,796,334. Insiders own 8.36% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Legal & General Group Plc acquired a new stake in shares of Achaogen during the 2nd quarter valued at about $168,000. Clear Harbor Asset Management LLC acquired a new position in Achaogen in the fourth quarter valued at about $177,000. Tower Research Capital LLC TRC boosted its position in Achaogen by 375.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 18,648 shares of the biopharmaceutical company’s stock valued at $201,000 after buying an additional 14,725 shares in the last quarter. Ardsley Advisory Partners acquired a new position in Achaogen in the second quarter valued at about $217,000. Finally, JPMorgan Chase & Co. boosted its position in Achaogen by 691.2% in the second quarter. JPMorgan Chase & Co. now owns 11,077 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 9,677 shares in the last quarter. Institutional investors and hedge funds own 85.84% of the company’s stock.
Achaogen Company Profile
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.